** Shares of drug developer Adial Pharmaceuticals ADIL.O rise as much as 68.8% to $1.30
** ADIL says U.S. FDA agreed with co's plan to use a specific approach called "in vitro bridging strategy" to support the development of AD04, to treat alcohol-use disorder in heavy-drinking patients
** This approach involves using existing data and lab tests to show that the new version of AD04 is equivalent to the previous version
** Co is developing the drug for its upcoming late-stage trial, set to begin this year
** Last year, AD04 showed safety and tolerability consistent with an existing treatment
** ADIL fell 42.3% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。